8/31/2020 8:16:45 AM
Regulus Therapeutics Reports Restructuring Of Sanofi And Oxford Loan Agreements
7/29/2020 8:13:30 AM
Regulus Therapeutics Announces FDA Orphan Drug Designation Of RGLS4326 For ADPKD Treatment
7/22/2020 8:14:39 AM
Regulus Therapeutics Completes Dosing In Phase 1 Multiple Ascending Dose Study Of RGLS4326
12/16/2019 8:19:35 AM
Cellectar Biosciences Announces Summary Data From 20 Patients Receiving Single Dose Of CLR 131 In Phase 2 CLOVER-1 Trial
12/16/2019 8:13:05 AM
Regulus Therapeutics Says FDA Lifted Partial Clinical Hold On Phase 1 Multiple Ascending Dose Clinical Study Of RGLS4326
9/12/2019 8:05:33 AM
Regulus Announces Publication In Nature Communications Identifying RGLS4326 As Promising Treatment For ADPKD
7/30/2019 8:21:46 AM
Regulus Therapeutics Appoints Cris Calsada As New CFO
6/11/2019 5:01:35 AM
Regulus Therapeutics Names Jake Nunn And Simos Simeonidis To Board
5/8/2019 9:21:14 AM
Wedbush Is Increasing Regulus Therapeutics Inc. (RGLS) FY20 Estimate To -1.09 From -2.11
5/8/2019 9:20:56 AM
Wedbush Is Raising Regulus Therapeutics Inc. (RGLS) Q4 20 Estimate To -0.29 From -0.55
5/8/2019 9:20:43 AM
Wedbush Is Raising Regulus Therapeutics Inc. (RGLS) Q3 20 Estimate To -0.28 From -0.53
5/8/2019 9:20:31 AM
Wedbush Is Raising Regulus Therapeutics Inc. (RGLS) Q2 20 Estimate To -0.27 From -0.52
5/8/2019 9:20:18 AM
Wedbush Is Raising Regulus Therapeutics Inc. (RGLS) Q1 20 Estimate To -0.26 From -0.50
5/8/2019 9:19:56 AM
Wedbush Is Increasing Regulus Therapeutics Inc. (RGLS) FY19 Estimate To -1.41 From -2.09
5/8/2019 9:19:35 AM
Wedbush Is Raising Regulus Therapeutics Inc. (RGLS) Q4 19 Estimate To -0.25 From -0.49
5/8/2019 9:19:21 AM
Wedbush Is Increasing Regulus Therapeutics Inc. (RGLS) Q3 19 Estimate To -0.27 From -0.53